Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the impact of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes (T2DM). Design and setting: A prospective pilot study of two months’ duration performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): 20 subjects with T2DM (10 men and 10 women, mean age: 57±13 years) were treated with liraglutide subcutaneously (0.6mg/daily for 2 weeks, followed by 1.2mg/daily) in addition to metformin (1500 mg/daily orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5±0.4 vs. 7.5±0.4%, p<0.0001). In addition, plasma ghrelin and glutathione (GSH) concentrations increased (8.2±4.1 vs. 13.6±7.3 pg/ml, p=0.0007 and 0.36±0.06 vs. 0.44±0.07 nmol/ml, p=0.0002, respectively), while serum lipid hydroperoxides and HO-1 decreased (0.11±0.05 vs. 0.04±0.07 pg/ml, p=0.0487 and 7.7±7.7 vs. 3.6±1.8 pg/ml, p=0.0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings appeared to be independent of the known effects of liraglutide on glucose metabolism.

Rizzo, M., Abate, N., Chandalia, M., Rizvi, A.A., Giglio, R.V., Nikolic, D., et al. (2015). Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 And Ghrelin Levels In Patients With Type 2 Diabetes: a prospective pilot study. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, jc20142291, 603-606 [10.1210/jc.2014-2291].

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 And Ghrelin Levels In Patients With Type 2 Diabetes: a prospective pilot study.

RIZZO, Manfredi;Giglio, RV;NIKOLIC, Dragana;MARINO GAMMAZZA, Antonella;MONTALTO, Giuseppe;
2015

Abstract

Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the impact of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes (T2DM). Design and setting: A prospective pilot study of two months’ duration performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): 20 subjects with T2DM (10 men and 10 women, mean age: 57±13 years) were treated with liraglutide subcutaneously (0.6mg/daily for 2 weeks, followed by 1.2mg/daily) in addition to metformin (1500 mg/daily orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5±0.4 vs. 7.5±0.4%, p<0.0001). In addition, plasma ghrelin and glutathione (GSH) concentrations increased (8.2±4.1 vs. 13.6±7.3 pg/ml, p=0.0007 and 0.36±0.06 vs. 0.44±0.07 nmol/ml, p=0.0002, respectively), while serum lipid hydroperoxides and HO-1 decreased (0.11±0.05 vs. 0.04±0.07 pg/ml, p=0.0487 and 7.7±7.7 vs. 3.6±1.8 pg/ml, p=0.0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings appeared to be independent of the known effects of liraglutide on glucose metabolism.
Rizzo, M., Abate, N., Chandalia, M., Rizvi, A.A., Giglio, R.V., Nikolic, D., et al. (2015). Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 And Ghrelin Levels In Patients With Type 2 Diabetes: a prospective pilot study. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, jc20142291, 603-606 [10.1210/jc.2014-2291].
File in questo prodotto:
File Dimensione Formato  
JCEM.2015.pdf

accesso aperto

Descrizione: pdf
Dimensione 171.01 kB
Formato Adobe PDF
171.01 kB Adobe PDF Visualizza/Apri
liraglutide.JPG

Solo gestori archvio

Descrizione: Pagine del sito dell'editore
Tipologia: Contratto con l'editore (ATTENZIONE: NON TRASFERIRE A SITO DOCENTE)
Dimensione 58.89 kB
Formato JPEG
58.89 kB JPEG   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/105647
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 75
social impact